An observational study in Heart Failure, sponsored by Impulse Dynamics. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by Impulse Dynamics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Heart Failure by Impulse Dynamics — 4 open to participants now, 6 under way, none of them phase 3. Heart Failure · Impulse Dynamics.
Among the 11 studies in Heart Failure by Impulse Dynamics, this one is one of 3 that started in 2025, is one of 4 observational ones, and was the 9th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →4 of the 11 studies in Heart Failure by Impulse Dynamics are open now, in 2 countries. Recruiting first, the newest first:
Impulse Dynamics · Sites in United States
Ages 18+
Impulse Dynamics · Sites in United States
Ages 18+
Impulse Dynamics · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 200 is close to the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 160 across the 7 interventional studies, 2,410 across the 4 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Impulse Dynamics is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
1 of the studies in Heart Failure by Impulse Dynamics that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06580392Impulse DynamicsCCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Heart Failure by Impulse Dynamics, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the impact of Cardiac Contractility Modulation (CCM) therapy on the initiation and up-titration of Guideline-Directed Medical Therapy (GDMT) in patients with heart failure (HF). This will be assessed by the change in Quad Medication Score (QMS) from baseline (pre-CCM) to 6-month following post-CCM device implant.
Design Prospective, non-randomized, comparison analysis of medication use and dosing at pre/post CCM therapy. The Fix-GDMT-HF study aims to enroll up to 200 subjects (100 in Investigational Arm and up to 100 in Registry Arm). Subjects identified not eligible to participate in the investigational arm can participate in the registry arm.
Method
Endpoints
Primary Endpoint:
Secondary Endpoints:
Patients
Investigational arm - 100 subjects complete the study with 12- month of follow-up.
Registry arm - restricted to 100 subjects
Sites 10 sites in Germany \& Italy. 10 sites in the USA.
Duration
The entire study is expected to take approximately 24 months or (until the target number of subjects has been reached), including the enrolment and follow-up periods.
Subject selection will be based on specific inclusion and exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with Heart failure with reduced (HFrEF) where the Ejection Fraction (EF) is ≤40%
- Historical LVEF assessed up to 6 months prior to consent by any modality can be used if available
Patients can have an active concomitant CRT device already - implanted provided the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change in Quad Medication Score
Change in the Quad Medication Score (QMS) from baseline (pre-CCM) to 6-month follow-up (post-CCM) of the Optimizer device implant
Time frame: 6 month
Change in loop diuretic dose
Change in loop diuretic dose from baseline to 6-month follow-up.
Time frame: 6-month
Change in eGFR
Change in eGFR from baseline to 6-month follow-up
Time frame: 6-month
Change in SBP
Change in SBP from baseline to 6-month follow-up.
Time frame: 6-month
Adverse events (AEs) associated with CCM therapy.
Adverse events (AEs) associated with CCM therapy.
Time frame: 12-month
Percentage of patients achieving maximal/optimal GDMT following CCM therapy
Percentage of patients achieving maximal/optimal GDMT following CCM therapy
Time frame: 12-month
GDMT adherence as measured by change in QMS score
GDMT adherence as measured by change in QMS score from 6 months (post-CCM) to 12 months (post-CCM).
Time frame: 12-month
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jun 2027, 28 months after the start.
Of 183 industry-sponsored observational studies under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's planned 28 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Impulse Dynamics